The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Patient preferences and perspectives on topical treatments for plaque psoriasis
|
Results from an online survey of adults with plaque psoriasis in the United States were published by Amstrong et al. in the Journal of Dermatological Treatment, highlighting their preferences and perspectives on topical treatments. A total of 507 patients were included; mean age was 46.3 years and 47% were female. Most participants reported their psoriasis symptoms as mild (31%) or moderate (59%), and the average number of topical treatments received was 2.5. |
| Key learnings |
| Areas most affected by psoriasis were the scalp (56%), elbows (48%), legs (excluding knees; 41%), intertriginous areas (39%), arms (excluding elbows; 33%), and knees (32%). Psoriasis affecting the scalp, elbows, and legs had the greatest effect on quality of life. |
| Topical therapies were the most preferred treatment option (76%), although 20% preferred pills and 4% injections. |
| In total, 130 patients were somewhat or very dissatisfied with their topical therapy, for reasons such as ineffectiveness in clearing psoriasis (67%), the need for multiple daily applications (53%), and treatments being messy or greasy (38%). Dissatisfied patients reported more severe symptoms at diagnosis (18% vs 7%), preferred injection treatments (9% vs 2%), wanted once-daily dosing (63% vs 27%), and favored non-steroidal products (26% vs 16%) compared with satisfied patients. |
| The most desired attributes to assist with topical treatment adherence were plaque improvement (68%), itch relief (68%), and ease of application (63%). |
| 90% of patients wanted more effective topical treatment options and a single topical therapy applicable to anywhere on the body. |
| These findings highlight key aspects of experiences and preferences of patients with plaque psoriasis, which can guide future treatment strategies and inform patient-centered care. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
